Zebra Biologics Inc. is using technology licensed from The Scripps Research Institute that accelerates the functional characterization of antibodies by pooling Abs that bind to a given target into a single cell-based reporter system. The biotech has used the technology to generate antibodies that agonize the previously intractable metabolic disease targets adiponectin receptor 1 and ADIPOR2.

Antibody generation typically relies on two core methods: an in vivo approach in which an antigen is injected into a mouse; or an in vitro approach such as phage display. Both approaches generate a large number of antibodies and are followed by multiple binding experiments to identify those with affinity to targets of interest.